FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017288701> ?p ?o ?g. }

• W2017288701 endingPage "288" @default.
• W2017288701 startingPage "277" @default.
• W2017288701 abstract "The insulin-like growth factor-1 receptor (IGF-1R) pathway is known to play a role in the acquisition of resistance to epidermal growth factor receptor (EGFR)-specific tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, its exact role in TKI resistance has so far remained unclear. Here, we interrogated the hypothesis that the IGF-1R may serve as a biomarker for, and may play a role in, intrinsic resistance to the EGFR-specific TKI gefitinib in NSCLC.Total-IGF-1R and phosphorylated (p)-IGF-1R expression levels were related to gefitinib sensitivity in 23 NSCLC cell lines. This sensitivity was re-evaluated after knocking down IGF-1R expression and after IGF-1R up-regulation through exogenous IGF-1 expression. The utility of IGF-1R expression as a predictive biomarker was also evaluated by immunohistochemistry (IHC) in 98 primary NSCLC samples from patients treated with gefitinib.Seventeen of the cell lines tested were resistant to gefitinib, whereas 3 cell lines were sensitive. The three remaining cell lines showed intermediate values. Thirteen resistant cell lines were found to be positive for total-IGF-1R expression, while all the sensitive cell lines were negative, resulting in a positive predictive value (PPV) of 81% for total-IGF-1R to predict resistance. Seven resistant cell lines exhibited high p-IGF-1R levels, whereas all 3 sensitive cell lines were negative for p-IGF-1R, resulting in a PPV of 100% for p-IGF-1R to predict resistance. Neither a knock-down of IGF-1R expression nor an activation of the IGF1-R pathway through exogenous IGF-1 expression affected gefitinib sensitivity. In primary NSCLC tissues, IGF-1R expression was found to be significantly higher in patients with progressive disease, i.e., showing gefitinib resistance, as compared to those with a complete or partial response.IGF-1R acts as a predictor for resistance to gefitinib in NSCLC cell lines and NSCLC patients, but does not seem to play a role in the intrinsic resistance to this drug. High total-IGF-1R and p-IGR-1R levels may predict such a resistance. Since the underlying mechanism does not appear to be related to proliferation induction, alternative pathways should be explored." @default.
• W2017288701 created "2016-06-24" @default.
• W2017288701 creator A5001270683 @default.
• W2017288701 creator A5020903489 @default.
• W2017288701 creator A5022735303 @default.
• W2017288701 creator A5025012859 @default.
• W2017288701 creator A5060374163 @default.
• W2017288701 creator A5064259481 @default.
• W2017288701 creator A5066153884 @default.
• W2017288701 creator A5070079018 @default.
• W2017288701 creator A5071851332 @default.
• W2017288701 creator A5080566517 @default.
• W2017288701 creator A5081654329 @default.
• W2017288701 date "2013-04-26" @default.
• W2017288701 modified "2023-10-07" @default.
• W2017288701 title "Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer" @default.
• W2017288701 cites W1998971866 @default.
• W2017288701 cites W2002937040 @default.
• W2017288701 cites W2003984225 @default.
• W2017288701 cites W2016717983 @default.
• W2017288701 cites W2019607817 @default.
• W2017288701 cites W2050604034 @default.
• W2017288701 cites W2058088773 @default.
• W2017288701 cites W2067613508 @default.
• W2017288701 cites W2078071018 @default.
• W2017288701 cites W2094025115 @default.
• W2017288701 cites W2095618958 @default.
• W2017288701 cites W2095673635 @default.
• W2017288701 cites W2104339838 @default.
• W2017288701 cites W2105026490 @default.
• W2017288701 cites W2107304950 @default.
• W2017288701 cites W2112096254 @default.
• W2017288701 cites W2113309935 @default.
• W2017288701 cites W2121260558 @default.
• W2017288701 cites W2121389354 @default.
• W2017288701 cites W2132157071 @default.
• W2017288701 cites W2138309116 @default.
• W2017288701 cites W2140334822 @default.
• W2017288701 cites W2142850084 @default.
• W2017288701 cites W2144722046 @default.
• W2017288701 cites W2152004755 @default.
• W2017288701 cites W2154349915 @default.
• W2017288701 cites W2158734599 @default.
• W2017288701 cites W2165462568 @default.
• W2017288701 cites W2166084034 @default.
• W2017288701 cites W2167341806 @default.
• W2017288701 doi "https://doi.org/10.1007/s13402-013-0133-9" @default.
• W2017288701 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4186686" @default.
• W2017288701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23619944" @default.
• W2017288701 hasPublicationYear "2013" @default.
• W2017288701 type Work @default.
• W2017288701 sameAs 2017288701 @default.
• W2017288701 citedByCount "78" @default.
• W2017288701 countsByYear W20172887012013 @default.
• W2017288701 countsByYear W20172887012014 @default.
• W2017288701 countsByYear W20172887012015 @default.
• W2017288701 countsByYear W20172887012016 @default.
• W2017288701 countsByYear W20172887012017 @default.
• W2017288701 countsByYear W20172887012018 @default.
• W2017288701 countsByYear W20172887012019 @default.
• W2017288701 countsByYear W20172887012020 @default.
• W2017288701 countsByYear W20172887012021 @default.
• W2017288701 countsByYear W20172887012022 @default.
• W2017288701 countsByYear W20172887012023 @default.
• W2017288701 crossrefType "journal-article" @default.
• W2017288701 hasAuthorship W2017288701A5001270683 @default.
• W2017288701 hasAuthorship W2017288701A5020903489 @default.
• W2017288701 hasAuthorship W2017288701A5022735303 @default.
• W2017288701 hasAuthorship W2017288701A5025012859 @default.
• W2017288701 hasAuthorship W2017288701A5060374163 @default.
• W2017288701 hasAuthorship W2017288701A5064259481 @default.
• W2017288701 hasAuthorship W2017288701A5066153884 @default.
• W2017288701 hasAuthorship W2017288701A5070079018 @default.
• W2017288701 hasAuthorship W2017288701A5071851332 @default.
• W2017288701 hasAuthorship W2017288701A5080566517 @default.
• W2017288701 hasAuthorship W2017288701A5081654329 @default.
• W2017288701 hasBestOaLocation W20172887012 @default.
• W2017288701 hasConcept C101544691 @default.
• W2017288701 hasConcept C121608353 @default.
• W2017288701 hasConcept C126322002 @default.
• W2017288701 hasConcept C170493617 @default.
• W2017288701 hasConcept C26375932 @default.
• W2017288701 hasConcept C2775960820 @default.
• W2017288701 hasConcept C2776256026 @default.
• W2017288701 hasConcept C2776362946 @default.
• W2017288701 hasConcept C2778820342 @default.
• W2017288701 hasConcept C2779438470 @default.
• W2017288701 hasConcept C2780580887 @default.
• W2017288701 hasConcept C2780689927 @default.
• W2017288701 hasConcept C2781197716 @default.
• W2017288701 hasConcept C42362537 @default.
• W2017288701 hasConcept C502942594 @default.
• W2017288701 hasConcept C54355233 @default.
• W2017288701 hasConcept C55493867 @default.
• W2017288701 hasConcept C71924100 @default.
• W2017288701 hasConcept C81885089 @default.
• W2017288701 hasConcept C86803240 @default.
• W2017288701 hasConceptScore W2017288701C101544691 @default.

• next